Dive Brief:

• Biobeat Technologies has raised $50 million to commercialize its cuffless blood pressure monitor in the U.S., the company said last week.
• The company sells a 24-hour ambulatory blood pressure monitoring patch that competes with traditional solutions that require patients to wear a cuff on their arm and carry a small recorder.
• Biobeat said traditional devices have been underused because of their frequent and disruptive inflation cycles. The company is pitching its chest-worn patch as a way to improve compliance.

Dive Insight:

Ambulatory blood pressure monitoring can detect forms of hypertension that may go unnoticed during one-time checks at the doctor’s office. Some people have elevated blood pressure in healthcare settings and normal blood pressure at home, or vice versa. Other people only have high blood pressure when asleep. 

Biobeat’s device assesses blood pressure by measuring the time it takes for a pressure wave from a heartbeat to move between two sites. The measurement, called the pulse wave transit time, is one of several ways that researchers have tried to estimate blood pressure using cuffless devices. Biobeat received 510(k) clearance for its latest device in January 2025.

New Biobeat investors Ally Bridge Group, OrbiMed Advisors and Elevage Medical led a $50 million Series B investment to support expanded commercialization in the U.S. An unnamed strategic investor also joined the round. Biobeat will use the money to try to establish its cuffless device as a go-to option for monitoring blood pressure in the 100 million hypertensive patients in the U.S. 

Physicians typically prescribe devices that consist of a cuff worn around the arm and a small, portable recorder to monitor blood pressure continually for 24 hours. The cuff inflates at regular intervals, such as every 30 minutes in the day and every 60 minutes at night, to take blood pressure readings. 

Because cuff inflation squeezes the arm, patients may have disrupted sleep while wearing the device. Movement can cause reading errors and some people remove cuffs, resulting in missing readings in many patients. An analysis of 1,141 Americans who wore blood pressure cuffs for 24 hours found that between 45% and 91.8% of patients had complete recordings, depending on the criteria used.

Advocates of cuffless devices view the design as a way to reduce the burdens of 24-hour ambulatory blood pressure monitoring and increase compliance. Yet U.S. cardiovascular health bodies recommended against the use of cuffless devices in 2025 guidelines. Noting the limited data on cuffless devices, the experts said there is no benefit to the technology.